Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 374Neoplasms 325Neoplasm Metastasis 289Leukemia, Myeloid, Acute 282Breast Neoplasms 276Colorectal Neoplasms 238Melanoma 196Ovarian Neoplasms 192Recurrence 185Multiple Myeloma 180Prostatic Neoplasms 157Pancreatic Neoplasms 156Lung Neoplasms 156Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 145Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 117Carcinoma, Renal Cell 111Stomach Neoplasms 110Advanced Solid Tumors 108Glioma 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Brain Neoplasms 104Lymphoma 103Lymphoma, Large B-Cell, Diffuse 102Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 90

Interventions

olaparib 1decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × BRCA1 Mutation × 1 year × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡